$256 Million is the total value of HARBOURVEST PARTNERS LLC's 26 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 83.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SWI | Sell | Solarwinds Corp. | $111,216,000 | -30.5% | 7,439,200 | -5.5% | 43.46% | -26.7% |
KLDO | Sell | Kaleido BioSciences, Inc. | $16,688,000 | -28.8% | 1,833,832 | -4.5% | 6.52% | -24.8% |
PGNY | Sell | Progyny, Inc. | $1,261,000 | -51.1% | 29,743 | -66.0% | 0.49% | -48.3% |
REAL | Exit | The RealReal, Inc. | $0 | – | -7,300 | -100.0% | -0.04% | – |
BDTX | Exit | Black Diamond Therapeutics, Inc. | $0 | – | -9,581 | -100.0% | -0.11% | – |
ARVN | Exit | Arvinas, Inc. | $0 | – | -16,666 | -100.0% | -0.14% | – |
PTI | Exit | Proteostasis Therapeutics, Inc. | $0 | – | -440,627 | -100.0% | -0.18% | – |
LYFT | Exit | Lyft, Inc. | $0 | – | -25,785 | -100.0% | -0.26% | – |
VCYT | Exit | Veracyte, Inc. | $0 | – | -23,591 | -100.0% | -0.28% | – |
PHR | Exit | Phreesia, Inc. | $0 | – | -24,562 | -100.0% | -0.29% | – |
CNST | Exit | Constellation Pharmaceuticals, Inc. | $0 | – | -49,614 | -100.0% | -0.37% | – |
Exit | Crispr Therapeutics AGnamen akt | $0 | – | -21,439 | -100.0% | -0.66% | – | |
SFIX | Exit | Stitchfix, Inc. | $0 | – | -66,571 | -100.0% | -0.67% | – |
PD | Exit | PagerDuty, Inc. | $0 | – | -67,891 | -100.0% | -0.68% | – |
NTNX | Exit | Nutanix, Inc. | $0 | – | -106,049 | -100.0% | -0.87% | – |
ISEE | Exit | IVERIC Bio, Inc. | $0 | – | -442,810 | -100.0% | -0.92% | – |
PS | Exit | PluralSight, Inc. | $0 | – | -176,807 | -100.0% | -1.12% | – |
ONEM | Exit | 1Life Healthcare, Inc. | $0 | – | -351,480 | -100.0% | -3.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Wayfair, Inc. | 25 | Q3 2023 | 83.5% |
Trevena, Inc. | 25 | Q4 2021 | 1.2% |
Finjan Holdings, Inc. | 23 | Q2 2020 | 18.5% |
Zuora, Inc. | 21 | Q3 2023 | 3.4% |
Evelo Biosciences, Inc. | 20 | Q1 2023 | 26.3% |
CytomX Therpeutics, Inc. | 19 | Q4 2021 | 2.3% |
LendingClub Corp. | 18 | Q3 2019 | 11.9% |
Rubius Therapeutics, Inc. | 18 | Q4 2022 | 21.4% |
Solarwinds Corp. | 17 | Q4 2022 | 60.4% |
Axcella Health, Inc. | 17 | Q2 2023 | 6.7% |
View HARBOURVEST PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SolarWinds Corp | February 14, 2022 | 3,719,600 | 2.3% |
N-able, Inc. | December 20, 2021 | 3,719,600 | 2.1% |
OncoMed Pharmaceuticals Inc | February 14, 2019 | 1,901,106 | 4.9% |
Wayfair Inc. | February 16, 2016 | 2,115,296 | 4.6% |
ENVIVIO INC | February 13, 2013 | 3,639,939 | 13.5% |
NETWORK ENGINES INCSold out | February 13, 2013 | 0 | 0.0% |
VOCALTEC COMMUNICATIONS LTD | August 06, 2010 | 243,689 | 2.1% |
CERAGON NETWORKS LTDSold out | July 26, 2007 | 0 | 0.0% |
VISTAPRINT LTDSold out | February 14, 2007 | 0 | 0.0% |
VOCALTEC COMMUNICATIONS LTD | May 26, 2006 | 1,218,444 | 24.4% |
View HARBOURVEST PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
40-APP | 2024-04-24 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR/A | 2022-05-26 |
13F-HR | 2022-05-13 |
View HARBOURVEST PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.